Related Experiment Video

Updated: Jul 14, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical

Thomas J Lynch1, Ed S Kim, Beth Eaby

  • 1Massachusetts General Hospital, Boston, Massachusetts 02114, USA. tlynch@partners.org

The Oncologist
|May 25, 2007
PubMed

Insights

Epidermal growth factor receptor inhibitors (EGFRIs) improve survival in cancer but cause skin reactions. A new grading system helps manage these toxicities, improving patient quality of life.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Epidermal growth factor receptor inhibitors (EGFRIs) improve survival in non-small cell lung cancer, pancreatic cancer, and colorectal cancer.
  • EGFRIs are associated with a spectrum of dermatologic reactions, considered a class effect regardless of drug type (monoclonal antibodies or tyrosine kinase inhibitors).
  • Current management of these toxicities relies on symptomatic treatment, with limited evidence-based guidelines.

Purpose of the Study:

  • To establish a consensus on managing dermatologic toxicities associated with EGFRIs.
  • To discuss underlying mechanisms and evaluate therapeutic interventions for EGFRI-induced skin reactions.
  • To develop a practical framework for healthcare professionals to manage these adverse events.

Main Methods:

  • An international, interdisciplinary forum in October 2006 convened experts to discuss EGFRI dermatologic toxicity.
  • Evaluation of commonly used therapeutic interventions for EGFRI-related skin reactions.
  • Development of a three-tiered, EGFRI-focused toxicity grading system for therapeutic decision-making.

Main Results:

  • A consensus was reached on management strategies for EGFRI-associated dermatologic reactions.
  • A novel three-tiered grading system for EGFRI-induced skin toxicity was proposed.
  • A stepwise approach to intervention, tailored to toxicity severity, was outlined.

Conclusions:

  • The proposed grading system provides a framework for therapeutic decision-making in EGFRI-related dermatologic toxicity.
  • Effective management of these skin reactions is crucial for maintaining patient quality of life during long-term EGFRI treatment.
  • This approach aims to be easily applicable by healthcare professionals for consistent patient care.

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...